Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Bittoni
P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.10-10 Lung Cancer Survival in Younger Patients (<40 Years): Analysis of Surveillance, Epidemiology and End Results Program Data
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-85 Real-World Gefitinib 1st Line Treatment of Patients With Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-63 Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-Pd1/Pd-L1 Treatment—Data From a Chinese Population
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)
Scientific Reports
Multidisciplinary
P2.01-36 Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond
Expert Review of Anticancer Therapy
Oncology
Pharmacology
MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients With Advanced NSCLC Receiving EGFR-TKIs
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-65 First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients With EGFR-Mutant Metastatic NSCLC Receiving TKIs
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary